Cellectar shares surge 12.66% premarket as company highlights 2026 strategic initiatives and 2025 clinical/regulatory milestones.
ByAinvest
Tuesday, Jan 13, 2026 4:48 am ET1min read
CLRB--
Cellectar Biosciences (NASDAQ: CLRB) surged 12.66% in premarket trading following the announcement of its strategic initiatives for 2026, including a presentation by CEO James Caruso at the 44th Annual JP Morgan Healthcare Conference. The news highlighted key 2025 milestones: FDA Breakthrough Therapy Designation for iopofosine I-131 in relapsed/refractory Waldenstrom's macroglobulinemia (WM), positive Phase 1b data for pediatric high-grade glioma, and $15.2 million in fundraising. Caruso emphasized momentum toward European conditional approval for iopofosine I-131 in 2027 and pipeline validation through clinical trials, positioning the company to advance regulatory pathways and create shareholder value. The premarket rally reflects investor optimism about Cellectar’s progress in targeted radiotherapeutics and its strategic focus on high-impact oncology indications.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet